English
Polski
Español
українська
Lifelong urate-lowering treatment in gout
Which patients require a lifelong urate-lowering treatment following the first acute gout attack, and in which patients this is not necessary?
2018-07-03
Which patients require a lifelong urate-lowering treatment following the first acute gout attack, and in which patients this is not necessary?
If colchicine in doses 1 g + 0.5 g is partly ineffective in a patient with acute gout, should it be continued at the same daily dose or is it better to switch to or add a nonsteroidal anti-inflammatory drug or a corticosteroid?
What should guide our decisions when selecting drugs used in the treatment of acute gout?
How to monitor disease activity in patients with giant cell arteritis (GCA)? Is it useful to measure interleukin 6 levels, or are inflammatory markers (ESR, CRP) sufficient?
What are the new implications for clinical practice of the new 2016 European League Against Rheumatism (EULAR) recommendations for the management of gout?
Are periarticular injections used in the treatment of acute gout flares?
According to the EULAR guidelines, in gout flares colchicine is recommended within 12 hours of the onset of symptoms. Because most patients frequently present after this time, the recommendation concerns self-administration of colchicine and treatment of subsequent flares. Can we use low-dose colchicine if the patient presents after 12 hours from the onset of symptoms? Or should we prefer nonsteroidal anti-inflammatory drugs or steroids?
Is it necessary to perform imaging studies looking for vasculitides, such as aortitis, in all patients with polymyalgia rheumatica (PMR)? What imaging studies are recommended?
What is the current role of febuxostat in the treatment of chronic gout?
Should patients with asymptomatic hyperuricemia undergo screening joint ultrasonography to search for uric acid deposits?
